KR20130110465A - A composition comprising an extract of hovenia dulcis for decreasing stress - Google Patents
A composition comprising an extract of hovenia dulcis for decreasing stress Download PDFInfo
- Publication number
- KR20130110465A KR20130110465A KR1020120032467A KR20120032467A KR20130110465A KR 20130110465 A KR20130110465 A KR 20130110465A KR 1020120032467 A KR1020120032467 A KR 1020120032467A KR 20120032467 A KR20120032467 A KR 20120032467A KR 20130110465 A KR20130110465 A KR 20130110465A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- pharmaceutical composition
- stress
- cortisol
- active ingredient
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 244000010000 Hovenia dulcis Species 0.000 title abstract description 30
- 235000008584 Hovenia dulcis Nutrition 0.000 title abstract description 30
- 230000003247 decreasing effect Effects 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 56
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 230000035882 stress Effects 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000013016 Hypoglycemia Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 230000006931 brain damage Effects 0.000 claims description 6
- 231100000874 brain damage Toxicity 0.000 claims description 6
- 208000029028 brain injury Diseases 0.000 claims description 6
- 206010016256 fatigue Diseases 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 230000020763 muscle atrophy Effects 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000036737 immune function Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 241000183024 Populus tremula Species 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 24
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 101800000414 Corticotropin Proteins 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 6
- 235000008586 Hovenia Nutrition 0.000 description 6
- 241000405398 Hovenia Species 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 6
- 229960000258 corticotropin Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 102400000739 Corticotropin Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 244000184734 Pyrus japonica Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000014311 Cushing syndrome Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010063493 Premature ageing Diseases 0.000 description 3
- 208000032038 Premature aging Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- -1 stearide Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000002438 stress hormone Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 헛개나무 추출물을 함유하는 스트레스 저하용 또는 코티졸 과다분비 억제용 조성물에 관한 것이다. The present invention relates to a composition for suppressing stress or inhibiting cortisol excess, which contains a hinoki extract.
현대 생활을 살아가는 대부분의 사람들은 육체적 또는 정신적 스트레스에 노출되어 있으며 이로 인하여 건강상 많은 문제점이 발생하고 있다. Most people living in modern life are exposed to physical or mental stress, which causes many health problems.
상기 스트레스라는 용어를 의학에 처음으로 적용한 캐나다의 내분비학자 세리에는 스트레스를 "신체에 가해진 어떤 외부자극에 대하여 신체가 수행하는 일반적이고 특징적인 반응" 이라 정의하였다. 또한, 세리에는 어떠한 종류의 스트레스 요인이라도 그에 따른 신체 반응은 매우 유사하다는 점과, 이러한 스트레스 요인이 오랫동안 지속되면 질병으로 발전할 수 있다는 점을 보고하였다.The Canadian endocrinologist Serie, who first applied the term stress to medicine, defined stress as "a general and characteristic response that the body performs on any external stimulus to the body." In addition, Serie reported that the physical response to any kind of stress factors is very similar and that these stress factors can develop into diseases if they persist for a long time.
스트레스 요인으로는 크게 외적 요인과 내적 요인으로 구분할 수 있다. 외적 요인으로는 소음, 강력한 빛, 열, 한정된 공간과 같은 물리적 환경, 무례함, 명령, 타인과의 충돌과 같은 사회적 관계, 조직사회, 지인의 죽음, 실직 등과 같은 개인적 사건 등을 들 수 있다. 내적 요인으로는 카페인 섭취, 흡연, 수면부족, 과도한 스케쥴 등의 생활습관, 비관적인 생각, 비현실적인 기대, 완벽주의 등과 같은 개인특성이 있을 수 있다.Stress factors can be divided into extrinsic factors and internal factors. External factors include personal circumstances such as noise, strong light, heat, a physical environment such as limited space, rudeness, orders, social relationships such as conflicts with others, organizational societies, acquaintances' deaths, and unemployment. Internal factors may include personal characteristics such as caffeine intake, smoking, lack of sleep, lifestyle habits such as excessive schedules, pessimistic thoughts, unrealistic expectations, perfectionism.
이러한 스트레스 요인이 너무 과도하거나 오래 지속되는 경우 또는 개인이 스트레스 상황을 극복할 힘이 약화되어 있는 경우 각종 정신질환으로 발전할 수 있다. 스트레스로 인해 흔히 생길 수 있는 정신질환은 적응장애, 불안장애, 기분장애, 식이장애, 성기능장애, 수면장애, 신체형장애, 알코올 및 물질사용장애 등이 속한다. These stressors can develop into a variety of mental illnesses if they are overdone or prolonged, or if the individual is weakened to overcome the stress situation. Common mental illnesses that can be caused by stress include adaptive disorders, anxiety disorders, mood disorders, dietary disorders, sexual dysfunction, sleep disorders, somatoform disorders, alcohol and substance use disorders.
또한, 스트레스는 신체질환의 발생 원인이나 악화 요인으로도 작용할 수 있다. 스트레스에 취약한 우리 몸의 기관인 근골격계, 위장관계, 심혈관계 등이 특히 스트레스에 영향을 많이 받는다.Stress can also act as a cause or an exacerbation of physical disease. Musculoskeletal, gastrointestinal, cardiovascular, etc., which are vulnerable to stress, are especially affected by stress.
구체적으로, 스트레스 요인에 대한 스트레스 반응은 자극 호르몬인 아드레날린이나 다른 호르몬이 혈중 내로 분비되어 우리 몸을 보호하려고 하는 반응으로, 위험에 대처해 싸우거나 그 상황을 피할 수 있는 힘과 에너지를 제공한다. Specifically, the stress response to stressors is a stimulant hormone, adrenaline or other hormone secreted into the blood that protects our body, providing the power and energy to cope with the danger or to avoid the situation.
스트레스 반응에 따른 신체의 변화는 다음과 같다.The change of the body according to the stress reaction is as follows.
- 근육, 뇌, 심장에 더 많은 혈액을 보낼 수 있도록 맥박과 혈압의 증가가 나타난다.- Increased pulse and blood pressure to send more blood to muscles, brain, and heart.
- 더 많은 산소를 얻기 위해 호흡이 빨라진다.- Breathing speeds up to get more oxygen.
- 행동을 할 준비 때문에 근육이 긴장한다.- The muscles are tense because of the preparation for action.
- 상황 판단과 빠른 행동을 위해 정신이 더 명료해지고 감각기관이 더 예민해진다.- For clarity and quick action, the mind becomes clearer and the senses become more sensitive.
- 위험에 대비한 중요한 장기인 뇌, 심장, 근육으로 가는 혈류가 증가한다.- Increased blood flow to the brain, heart, and muscle, critical organs for risk.
- 위험한 시기에 혈액이 가장 적게 요구되는 곳인 피부, 소화기관, 신장, 간으로 가는 혈류는 감소한다.- Reduced blood flow to the skin, digestive system, kidneys, and liver, where blood is least needed in dangerous times.
- 추가 에너지를 위해서 혈액 중에 있는 당, 지방, 콜레스테롤의 양이 증가한다.- The amount of sugar, fat and cholesterol in the blood increases for additional energy.
- 외상을 입었을 때 출혈을 방지하기 위해 혈소판이나 혈액응고인자가 증가한다.- Platelets or blood clotting factors increase to prevent bleeding when you have trauma.
이러한 스트레스로 인한 신체 반응의 핵심은 스트레스가 각종 호르몬과 신경전달물질의 분비와 촉진을 변화시키는 것이다. The key to this body reaction is that stress changes the secretion and promotion of various hormones and neurotransmitters.
상기 호르몬 중 코티졸(cortisol)은 스트레스를 인지한 뇌에서 분비된 부신피질자극호르몬(ACTH)에 의하여 자극받은 부신피질에서 분비되는 호르몬이다. 상기 코티졸은 신체가 각종 스트레스를 받을 때 정상적인 생리적인 기능을 유지하도록 하는 중요한 역할을 한다. 만약, 코티졸이 없다면 인체는 여러 가지 스트레스에 효과적으로 대응하지 못할 것이다.Among these hormones, cortisol is a hormone secreted from the adrenal cortex stimulated by the corticotropin-stimulating hormone (ACTH) secreted by the stress-perceived brain. The cortisol plays an important role in maintaining the normal physiological function when the body is subjected to various stresses. If there is no cortisol, the human body will not be able to effectively cope with various stresses.
다만, 만성 스트레스에 의하여 코티졸이 과다 분비되는 경우 면역 기능을 억제하고 조직 재건을 위해 필요한 단백질의 생성을 늦추며, 신경세포의 손실을 가져오고, 뇌 손상, 뼈 손실(골다공증), 근육 위축, 복부지방의 축적, 정신병, 조기 노화 및 사망을 초래할 수 있다. 또한, 만성 스테레스에 의한 장기간 코티졸의 과다분비는 고혈압과 저혈당을 초래할 수 있다.However, when cortisol is excessively secreted by chronic stress, it inhibits immune function, slows the production of protein necessary for tissue reconstruction, causes loss of nerve cells, and causes brain damage, bone loss (osteoporosis), muscle atrophy, Fat accumulation, mental illness, premature aging, and death. In addition, overdose of long-term cortisol by chronic sterilization may lead to hypertension and hypoglycemia.
따라서 스트레스에 노출되어 있는 현대인의 건강을 위하여 스트레스를 해소 또는 저하시키고 코티졸의 과다분비를 억제할 필요가 있다.Therefore, for the health of the modern people who are exposed to stress, it is necessary to relieve or reduce the stress and to suppress the excessive secretion of cortisol.
한편, 천연물로부터 인간의 질병을 예방 또는 치료할 수 있는 신물질을 찾고자 하는 시도는 과거부터 많은 과학자들의 연구 대상이 되어 왔다. 그간 이들 자원을 이용한 의약품의 개발로 현재 사용되고 있는 의약품의 50% 이상이 천연물로부터 유래된 것이고, 미국의 경우 사용하는 의약품 중 30%가 식물로부터 얻어진 것에 이른다.On the other hand, attempts to find new substances that can prevent or treat human diseases from natural products have been studied by many scientists from the past. In the meantime, more than 50% of medicines currently used for the development of medicines using these resources are derived from natural products, and in the United States, 30% of the medicines used are derived from plants.
우리나라의 경우는 예로부터 한의학 이론을 바탕으로 하는 한방요법이나 민간요법 등에 의한 생약 추출물을 약제로서 사용해 왔다. In Korea, herbal medicine extracts based on oriental medicine theory or traditional therapies based on oriental medicine theory have been used as medicines in Korea.
이중 헛개나무(Hovenia dulcis)는 갈매나무과 낙엽활엽교목으로 경기, 강원 이남의 표고 50-800m에 분포하고 있으며, 일본, 중국에서도 분포하고 있다. 상기 헛개나무 추출물은 그동안 간기능 보호활성이 우수한 것으로 널리 알려져 왔으나, 스트레스를 저하시키는 작용효과 또는 코티졸 과다분비를 억제하는 작용효과에 대해서는 전혀 보고된 바가 없다. Hovenia dulcis is a deciduous broad-leaved arboreous tree, distributed at 50-800m above sea level in Gyeonggi Province and south of Kangwon, and distributed in Japan and China. Although the Hovenia dulcis extract has been widely known to have excellent hepatic function-protecting activity, there has been no report on the effect of suppressing stress or the action of inhibiting cortisol excess.
본 발명자들은 헛개나무 추출물의 스트레스 저하 또는 코티졸 과다분비 억제 효과를 발견하여 본 발명을 발명하게 되었다.The inventors of the present invention have discovered the effect of suppressing stress or cortisol excess secretion of Hovenia dulcis extract and invented the present invention.
본 발명의 목적은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for lowering stress which contains a hinoki extract as an active ingredient.
본 발명의 다른 목적은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for inhibiting cortisol overdose, which comprises a Hodgkin's extract as an active ingredient.
본 발명의 또 다른 목적은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 식품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a food composition for stress reduction which contains Hovenia dulcis extract as an active ingredient.
본 발명의 다른 목적은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for inhibiting cortisol overdose, which comprises a Hodgkin's extract as an active ingredient.
본 발명은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for lowering stress comprising Hovenia dulcis extract as an active ingredient.
또한, 본 발명은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for inhibiting cortisol overdose, which comprises a hodgkin's extract as an active ingredient.
또한, 본 발명은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for stress reduction comprising an extract of Hovenia dulcis as an active ingredient.
또한, 본 발명은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for inhibiting cortisol overdose, which contains a hodgkin's extract as an active ingredient.
상기 약학적 조성물 또는 식품 조성물은 코티졸 과다분비로 인한 면역기능 저하, 신경세포 손실, 뇌 손상, 근육 위축, 비만, 정신병, 노화, 고혈압, 저혈당, 당뇨 및 만성피로를 예방한다.The pharmaceutical composition or food composition prevents immune function degradation, neuronal loss, brain damage, muscle atrophy, obesity, psychosis, aging, hypertension, hypoglycemia, diabetes and chronic fatigue due to cortisol oversecretion.
상기 헛개나무 추출물은 헛개나무의 모든 부분으로부터 추출될 수 있으며, 그 중에서 헛개나무 과병으로부터 추출되는 것이 바람직하다. The hinoki extract may be extracted from all parts of the hinoki tree, and is preferably extracted from the hinoki hinoki.
또한, 상기 헛개나무 추출물은 물, 알코올 또는 이들의 혼합물로부터 선택되는 추출용매로 추출될 수 있으며, 열수 가압 추출되는 것이 바람직하다.In addition, the Hovenia dulcis extract may be extracted with an extraction solvent selected from water, alcohol or a mixture thereof, and is preferably hydrothermally extracted.
본 발명의 헛개나무 추출물은 코티졸 분비량을 억제하며, 스트레스를 저하하는 작용효과를 나타낸다.The Hovenia dulcis extract of the present invention suppresses the secretion amount of cortisol and exhibits a stress-reducing action effect.
도 1은 헛개나무 추출물에 의한 혈중 코티졸 수준 강하효과를 확인한 도표이다.
도 2는 헛개나무 추출물에 의한 혈중 ACTH 수준 강하효과를 확인한 도표이다.FIG. 1 is a graph showing the effect of lowering the cortisol level in blood by Hovenia dulcis extract.
FIG. 2 is a chart showing the ACTH level lowering effect by the Hovenia dulcis extract. FIG.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 헛개나무 추출물을 유효성분으로 함유하는 약학적 조성물 또는 식품 조성물을 제공한다. The present invention provides a pharmaceutical composition or food composition containing Hovenia dulcis extract as an active ingredient.
헛개나무Hinoki 추출물의 제조방법 Method of producing extract
상기 헛개나무 추출물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정되지 않는다:The hinoki extract is preferably but not limited to be produced by a manufacturing method comprising the following steps:
(1) 헛개나무에 혼입된 이물질을 제거하고 세척하는 단계;(1) removing foreign matter and washing the foreign matters mixed in the horny wood;
(2) 세척한 헛개나무에 추출용매를 가하여 추출물을 추출하는 단계;(2) extracting the extract by adding an extraction solvent to the washed hinoki wood;
(3) 추출물을 감압농축하는 단계;(3) concentrating the extract under reduced pressure;
(4) 헛개나무 농축액을 여과하는 단계; 및(4) filtering the Houttuynia concentrate; And
(5) 여과한 추출물을 건조하는 단계.(5) drying the filtered extract.
본 발명에서 사용되는 헛개나무는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 또한, 상기 헛개나무는 한국산, 일본산 또는 중국산 헛개나무를 모두 포함한다.The hinoki used in the present invention can be used without limitation, such as cultivated or commercially available hinoki. In addition, the hinoki includes all of Korean, Japanese or Chinese hinoki.
상기 헛개나무는 헛개나무 전체를 사용할 수 있으며, 잎, 뿌리, 목질부, 과병 또는 이들의 혼합물을 사용할 수 있다. 이 중에서 헛개나무 과병(果柄)을 사용하는 것이 가장 바람직하다.The hinoki can be the entire hinoki tree, and can be leaves, roots, woody plants, deadly diseases or a mixture thereof. Among them, it is most preferable to use the Houttree tree.
단계 (1)의 세척은 1 ~ 5회 반복하는 것이 바람직하다.The washing of step (1) is preferably repeated one to five times.
단계 (2)의 추출은 진탕 추출, Soxhlet 추출 또는 환류 추출 방법을 이용할 수 있으나 이에 한정되지 않는다. The extraction of the step (2) can be performed by shaking extraction, Soxhlet extraction, or a reflux extraction method, but is not limited thereto.
추출용매로는 물, 알코올 또는 이들의 혼합물을 사용할 수 있으며, 열수 가압 추출하는 것이 가장 바람직하다. 상기 추출용매로는 준비된 헛개나무의 3 내지 10배 중량의 추출용매를 가하여 추출하는 것이 바람직하다.As the extraction solvent, water, alcohol or a mixture thereof can be used, and it is most preferable to perform hydrothermal extraction. The extraction solvent is preferably extracted by adding an extraction solvent having a weight of 3 to 10 times the weight of the prepared hinoki.
상기 열수 가압 추출은 압력은 1.1 ~ 2 기압이 바람직하고, 1.2 ~ 1.5 기압이 더욱 바람직하다.The hydrothermal pressure extraction is preferably performed at a pressure of 1.1 to 2 atm, more preferably at a pressure of 1.2 to 1.5 atm.
또한, 열수 가압 추출시 온도는 60 ~ 100 ℃인 것이 바람직하며, 80 ~ 100 ℃인 것이 더욱 바람직하다. 또한, 추출시간은 2 내지 24시간인 것이 바람직하며, 추출회수는 1 내지 5회인 것이 바람직하다.In addition, the temperature during hydrothermal extraction is preferably 60 to 100 ° C, more preferably 80 to 100 ° C. The extraction time is preferably 2 to 24 hours, and the extraction time is preferably 1 to 5 times.
단계 (3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하다. 단계 (3)에서 헛개나무 추출액을 고형분 40% 이상이 되도록 농축하는 것이 바람직하다. It is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in the step (3). In step (3), it is preferable to concentrate the extract of Hovenia dulcis so as to have a solid content of 40% or more.
단계 (5)의 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조 방법을 이용할 수 있으나, 이에 한정되지 않는다.The drying in step (5) may be performed by vacuum drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
약학적 조성물Pharmaceutical composition
본 발명은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for lowering stress comprising Hovenia dulcis extract as an active ingredient.
또한, 본 발명은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for inhibiting cortisol overdose, which comprises a hodgkin's extract as an active ingredient.
본 발명의 헛개나무 추출물을 함유하는 약학적 조성물은 코티졸 과다분비 억제를 통하여 면역기능 저하, 신경세포 손실, 뇌 손상, 근육 위축, 비만, 정신병, 조기 노화, 위장질환, 고혈압, 저혈당, 당뇨, 만성피로를 예방할 수 있다.The pharmaceutical composition containing the bark extract of the present invention is characterized by a decrease in immune function, neuronal loss, brain damage, muscle atrophy, obesity, psychosis, premature aging, gastrointestinal diseases, hypertension, hypoglycemia, diabetes, chronic You can prevent fatigue.
본 발명의 헛개나무 추출물을 유효성분으로 함유하는 약학적 조성물은 약학적 조성물의 총 중량에 대하여 0.1 내지 50 중량%로 포함하는 것이 바람직하나 이에 한정되지 않는다.The pharmaceutical composition containing the Hovenuo extract of the present invention as an active ingredient is preferably contained in an amount of 0.1 to 50% by weight based on the total weight of the pharmaceutical composition, but is not limited thereto.
본 발명의 약학적 조성물은 실제 임상 투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제 및 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. The pharmaceutical compositions of the present invention can be administered in various formulations, oral and parenteral, in actual clinical administration. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants which are usually used.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제 및 캡슐제 등이 포함되며, 이러한 고형 제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스 및 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘, 스티레이드, 탈크 같은 윤활제도 사용될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and the like, which may be used in the pharmaceutical compositions of the present invention at least one excipient such as starch, calcium carbonate, sucrose, It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium, stearide, and talc may also be used.
경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 및 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 및 보존제 등이 포함될 수 있다. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제가 포함된다. 비수성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세롤 및 젤라틴 등이 사용될 수 있다. 본 발명의 약학적 조성물은 비경구 투여시 피하주사, 정맥주사 또는 근육내 주사를 통하여 투여될 수 있다. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. Witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like may be used as a base for suppositories. The pharmaceutical composition of the present invention can be administered by parenteral administration by subcutaneous injection, intravenous injection, or intramuscular injection.
본 발명의 약학적 조성물의 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르며, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서 본 발명의 추출물은 1일 0.0001 내지 100 mg/kg으로 투여하는 것이 바람직하다. 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 다만, 상기 투여량의 본 발명의 범위를 한정하는 것은 아니다.The dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, and can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg per day. The administration may be carried out once a day or divided into several doses. However, the scope of the present invention is not limited to these dosages.
본 발명의 약학적 조성물은 스트레스 저하 또는 코티졸 과다분비 억제를 위하여 단독으로, 또는 수술, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, chemotherapy, and biological response modifiers for stress reduction or cortisol over secretion inhibition.
식품 조성물Food composition
본 발명은 헛개나무 추출물을 유효성분으로 함유하는 스트레스 저하용 식품 조성물을 제공한다.The present invention provides a food composition for lowering stress which contains Hovenia dulcis extract as an active ingredient.
또한, 본 발명은 헛개나무 추출물을 유효성분으로 함유하는 코티졸 과다분비 억제용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for inhibiting cortisol overdose, which contains a hodgkin's extract as an active ingredient.
본 발명의 헛개나무 추출물을 함유하는 식품 조성물은 코티졸 과다분비 억제를 통하여 면역기능 저하, 신경세포 손실, 뇌 손상, 근육 위축, 비만, 정신병, 조기 노화, 위장질환, 고혈압, 저혈당, 당뇨, 만성피로를 예방할 수 있다.The food composition containing the bark extract of the present invention is immune suppression, neuronal loss, brain damage, muscle atrophy, obesity, psychosis, premature aging, gastrointestinal diseases, hypertension, hypoglycemia, diabetes, chronic fatigue Can be prevented.
본 발명의 식품 조성물은 헛개나무 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 함량은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 약학적 조성물은 식품의 총중량에 대하여 0.01 내지 15 중량%로 가할 수 있다. The food composition of the present invention can be used as it is, or can be used with other food or food ingredients, and can be suitably used according to conventional methods. The content of the active ingredient may be suitably determined according to the intended use (prevention, health or therapeutic treatment). In general, the pharmaceutical composition of the present invention may be added at 0.01 to 15% by weight relative to the total weight of the food in the manufacture of food or beverage.
또한, 상기 식품 조성물의 종류에는 특별한 제한이 없다. 본 발명의 조성물을 첨가할 수 있는 식품의 예로는 음료, 껌, 비타민 복합제, 드링크제 등의 건강기능성 식품이 있으며, 통상적인 의미에서의 식품 조성물을 모두 포함한다. 상기 식품 조성물로는 복용하기 편한 건강기능성 음료가 가장 바람직하다.There is no particular limitation on the kind of the food composition. Examples of foods to which the composition of the present invention can be added include health functional foods such as beverages, gums, vitamin complexes, and drinks, and include food compositions in a conventional sense. As the food composition, a health functional beverage which is easy to take is most preferable.
본 발명의 건강기능성 음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트릴톨 등의 당알콜이다. 또한, 상술한 것 이외의 향미제(사카린, 아스파르탐 등)을 사용할 수 있다.The health functional beverage of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol. Flavoring agents (saccharin, aspartame, etc.) other than those described above may also be used.
본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. The food composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예 및 실험예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments and experimental examples are provided to facilitate understanding of the present invention. However, the following examples and experimental examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples and experimental examples.
<< 실시예Example > > 헛개나무Hinoki 추출물의 제조 Preparation of extract
헛개나무 과병으로부터 이물질을 제거하고, 세척탱크에 넣고 2회 세척하였다. 세척한 헛개나무 과병 약 450 kg을 추출기에 넣고 정수를 약 1500 kg 정도 첨가하여 1.2기압에서 95 ℃ 이상 4시간 이상 가열, 가압 추출하였다. 1차 추출한 헛개나무 과병 추출액를 추출기에 넣고 정수를 약 1500Kg 정도 첨가하여 1.2기압에서 95 ℃ 이상 4시간 이상 가열, 가압하여 2차 추출하였다. 상기 2차 추출한 헛개나무 과병 추출액을 감압 700 mmHg, 온도 60 ℃에서 고형분 40 % 이상이 되도록 농축하였다. 수득한 헛개나무 과병 추출 농축액을 50 마이크로 필터로 통과시켜 여과하였다. 여과된 액을 배합탱크에 옮겨 헛개나무 과병 추출 농축액(고형분 40%)과 덱스트린 10:6비율로 계량하여 투입한 후 50 ℃로 30분 이상 교반, 혼합하였다. 배합탱크에서 90 ℃에서 30분간 가열 살균 후 40 ℃ ~ 50 ℃로 냉각시켰다. 상기 냉각된 혼합액을 Spray dryer로 분무 건조하였다(Inlet temp : 180℃, Outlet temp : 90℃).The foreign matter was removed from the Hovenia japonica, placed in a washing tank and washed twice. About 450 kg of washed Hovenia japonica were put into an extractor, and about 1500 kg of water was added. The first extract of Hovenia japonica extract was placed in an extractor, and about 1500 Kg of purified water was added. The mixture was heated at 1.2 atm over 95 ℃ for 4 hours, and then subjected to secondary extraction. The second-extracted Hovenia dulcis extract was concentrated to a solid content of 40% or more at a reduced pressure of 700 mmHg at a temperature of 60 ° C. The resulting Hovenia japonica extract concentrate was filtered through a 50 micro-filter. The filtrate was transferred to a mixing tank and weighed in a ratio of 10: 6 of dextrin to a concentrate (solid content: 40%) of Hovenia dulcis extract. The mixture was stirred at 50 ° C for 30 minutes or more. The mixture was sterilized by heating at 90 DEG C for 30 minutes in a mixing tank and then cooled to 40 DEG C to 50 DEG C. [ The cooled mixed solution was spray-dried with a spray dryer (Inlet temp: 180 ° C, Outlet temp: 90 ° C).
<< 실험예Experimental Example > > 헛개나무Hinoki 추출물의 스트레스 저하 효과 확인 Identification of stress-reducing effect of extract
시험물질의 조제Preparation of test substances
상기 실시예에서 제조된 헛개나무 추출물을 전자저울 (CP323S, LA230S, Sartorius, Germany)로 칭량하여 조제병에 넣었다. 주사용수를 각각의 조제병에 일부 가하여 현탁 시킨 후, 다시 주사용수를 첨가하여 규정농도 (10mg/mL)로 조제하였다.The hinoki extracts prepared in the above examples were weighed with an electronic balance (CP323S, LA230S, Sartorius, Germany) and placed in a preparation bottle. Syringes were added to each preparation bottle to suspend them, and then added with water for injection to prepare a prescribed concentration (10 mg / mL).
사용동물Used animal
수컷 ICR 마우스 30마리(5주령)를 Central Lab. Animal Inc., Korea 에서 구입하였다. 상기 마우스들을 검역실로 반입하여 3일간 순화시키고, 동물실로 옮겨 4일간 순화를 실시하였다. 반입시 동물의 외관 검사를 실시한 후, 전자저울 (CP622, Sartorius, Germany)로 체중을 측정하였다. Male ICR mice (5 weeks old) were treated with Central Lab. Animal Inc., Korea. The mice were transferred into a quarantine chamber, purified for 3 days, transferred to an animal room, and purified for 4 days. The animals were visually inspected at the time of loading and then weighed with an electronic balance (CP622, Sartorius, Germany).
상기 7일간의 순화기간 중에 매일 1회 일반증상을 관찰하였다. The general symptoms were observed once a day during the 7 day purification period.
순화기간 종료일에는 체중을 측정한 후, 일반증상 및 체중변화를 확인하여 동물의 건강상태를 평가하였다. 그 결과, 모든 동물에서 일반증상 및 체중변화의 이상은 관찰되지 않았다.At the end of the purifying period, the body weight was measured, and general symptoms and changes in body weight were checked to evaluate the health status of the animals. As a result, no abnormalities in general symptoms and weight changes were observed in all animals.
군의 분리Separation of a group
검역 순화기간 종료 시, 건강상태에 이상이 없는 동물 중 순화기간 종료 일의 평균체중에 가까운 20 마리를 선발하였다. 선발된 동물은 체중을 기초로 하여 각 군의 평균체중이 균등하도록 군당 10 마리씩 투여군 및 대조군의 총 2군으로 군을 분리하였다.At the end of the quarantine period, 20 animals that had no abnormality in health status were selected, which were close to the average weight at the end of the purification period. The selected animals were divided into two groups of 10 mice per group and control group, so that the average weight of each group was uniform based on body weight.
투여방법 및 투여횟수, 용량Method of administration and frequency of administration, dose
투여는 경구투여용 존데를 부착한 일회용 주사기 (1mL, Doowon meditec Co., Korea)를 이용하여 매일 1회, 100 mg/kg으로 3주간 연속적으로 투여군의 위내에 강제 투여하였다.The administration was forcibly administered in the stomach of the administration group continuously for 3 weeks at a dose of 100 mg / kg once a day using a disposable syringe (1 mL, Doowon meditec Co., Korea) with orally administered sonde.
스트레스 환경 설정(유영운동)Stress setting (swimming exercise)
유영운동을 위해 50W×40D×50H (cm)의 플라스틱 수조를 준비하고, 약 35 cm 높이까지 멸균수를 채운 후 수중히터 (Aquarium Heater 3615200, EIEIM GmbH & Co. KG., Germany)를 이용하여 25 ± 2 ℃의 수온을 유지시켰다.For swimming, a plastic water tank of 50W × 40D × 50H (cm) was prepared, filled with sterilized water to a height of about 35 cm, and then immersed in a water bath (Aquarium Heater 3615200, EIEIM GmbH & Co. KG, Germany) The water temperature of ± 2 ° C was maintained.
시험물질 투여 1 시간째에 마우스 체중의 4 %에 해당하는 무게 추를 마우스 꼬리에 부착하여 지속적으로 수영할 수 있도록 준비하였다.One hour after administration of the test substance, a weight corresponding to 4% of the mouse weight was attached to the tail of the mouse to prepare for continuous swimming.
시험물질 투여 3 주째에 유영운동을 모든 동물에게 1 시간 동안 강제 수영을 시켰다.At the third week of the test substance administration, swimming was performed by forced swimming for 1 hour to all animals.
혈액 내 호르몬 분석Hormone analysis in blood
유영운동이 끝난 후 동물은 Isoflurane (Lot No.: ASJ9AE, Choongwae Pharma Corp., Korea)으로 마취한 후 개복하여 복대정맥으로부터 혈액을 채취하였다. Kit 를 이용하여 혈액 내 코티졸 (Lot No.: 011911, Endocrine Technologies, Inc., U.S.A.)및 ACTH (Lot No.: 1415, MD Biosciences, GmbH., Germany)의 농도를 측정하였다. 그 결과는 하기 표 1과 같다.After the swimming session, the animals were anesthetized with Isoflurane (Lot No .: ASJ9AE, Choongwae Pharma Corp., Korea), and the blood was collected from the abdominal vein. The concentration of cortisol (Lot No .: 011911, Endocrine Technologies, Inc., U.S.A.) and ACTH (Lot No .: 1415, MD Biosciences, GmbH, Germany) in the blood was measured using Kit. The results are shown in Table 1 below.
[표 1][Table 1]
또한, 상기 표 1의 데이터 중 대조군과 투여군의 코티졸의 혈중 농도를 도 1에, 대조군과 투여군의 ACTH의 혈중 농도를 도 2에 각각 나타내었다.The blood concentration of cortisol in the control group and the administration group in the data of Table 1 is shown in Fig. 1, and the blood concentration of ACTH in the control group and the administration group is shown in Fig. 2, respectively.
상기 표 1 및 도 1에서 확인되는 바와 같이, 스트레스 호르몬인 코티졸은 본 발명의 헛개나무 추출물을 투여하지 않은 대조군보다 투여군에서 혈중 농도가 약 25% 감소하였다. As shown in Table 1 and FIG. 1, the stress hormone cortisol had a blood concentration of about 25% lower in the administration group than the control group without the Hovenia dulcis extract of the present invention.
또한, 표 1 및 도 2에서 확인되는 바와 같이, 부신피질자극호르몬인 ACTH는 투여군에서의 혈중 농도가 대조군보다 약 13% 감소하였다.In addition, as shown in Table 1 and Fig. 2, the ACTH, the adrenocorticotrophic hormone, was reduced by about 13% in the blood group in the administration group than the control group.
이로써, 헛개나무 추출물이 스트레스 호르몬인 코티졸의 수준을 유의미하게 저감시키는 것을 확인하였다.Thus, it was confirmed that the extract of Hovenia dulcifera significantly reduced the level of the stress hormone cortisol.
따라서, 스트레스로 인한 코티졸의 과다분비시 헛개나무 추출물을 투여함으로써 코티졸의 수준을 유효하게 낮출 수 있음을 알 수 있다.Therefore, it can be seen that when cortisol is excessively secreted due to stress, the level of cortisol can be effectively lowered by administering Hovenia dulcis extract.
<약학적 제제의 제조예>≪ Preparation example of pharmaceutical preparation >
1. 제제예 1 : 산제의 제조1. Formulation Example 1: Preparation of powder
실시예의 헛개나무 추출물 2 g2 g of hinoki extract of Example
유당 1 gLactose 1 g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
2. 제제예 2 : 정제의 제조2. Formulation Example 2: Preparation of tablets
실시예의 헛개나무 추출물 100 mg100 mg of Hovenia dulcis extract of Example
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후 통상의 정제의 제조방법에 의하여 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting by a conventional method for producing tablets.
3. 제제예 3 : 캡슐제의 제조3. Formulation Example 3: Preparation of capsules
실시예의 헛개나무 추출물 100 mg100 mg of Hovenia dulcis extract of Example
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분을 혼합한 후 통상의 젤라틴의 제조방법에 의하여 젤라틴 캡슐에 충전하여 정제를 제조한다.After mixing the above components, they are filled into gelatin capsules by a conventional method for producing gelatin to prepare tablets.
4. 제제예 4 : 주사제의 제조4. Formulation Example 4: Preparation of injection
실시예의 헛개나무 추출물 100 mg100 mg of Hovenia dulcis extract of Example
주사용 증류수 적량Distilled water for injection
pH 조절제 적량pH adjuster
통상의 주사제의 제조방법에 따라 활성성분을 주사용 증류수에 용해하고 pH를 약 7.5로 조절한 다음 전체를 주사용 증류수로 2 ml 용량의 앰플에 충진하고 멸균시켜서 주사제를 제조한다.The active ingredient is dissolved in distilled water for injection, the pH is adjusted to about 7.5, and the whole is filled with ampoule of 2 ml capacity for distilled water for injection and sterilized to prepare an injection.
<건강음료의 제조예>≪ Example of production of health drink &
1. 제조예 11. Preparation Example 1
멸균하여 준비한 1000ml 정제수에 실시예에서 제조한 헛개나무 추출물 3.6 g을 첨가한다. 여기에 구연산 1000mg과 매실농축액 2g, 올리고당 100g, 타우린 1g을 첨가하여 약 60분간 85℃에서 교반하여 가열한다. 이렇게 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 본 발명의 건강음료를 제조하였다.To 1000 ml purified water prepared by sterilization, 3.6 g of Hovenia bran extract prepared in the Example is added. 1000 mg of citric acid, 2 g of plum concentrate, 100 g of oligosaccharide and 1 g of taurine are added, and the mixture is stirred at 85 캜 for about 60 minutes and heated. The thus-prepared solution was filtered and sterilized in a sterilized 2 L container, sealed and stored in a refrigerator to prepare a health drink of the present invention.
2. 제조예 22. Preparation Example 2
헛개나무 추출물 0.4g을 사이다와 같은 소프트 음료 시럽 100ml에 용해하는 것을 제외하고는 제조예 1과 동일하게 제조하였다.0.4 g of Hovenia dulcis extract was dissolved in 100 ml of a soft beverage syrup such as cider.
3. 제조예 33. Preparation Example 3
헛개나무 추출물 0.25g을 각종 스포트 드링크 100ml에 첨가한 것을 제외하고는 제조예 1과 동일하게 제조하였다.0.25 g of Hovenia dulcis Thunb extract was added to 100 ml of various sports drinks.
4. 제조예 44. Preparation Example 4
헛개나무 추출물 0.15g을 각종 과일, 야채류, 해조류, 콩, 천연약제 등의 즙 또는 그 추출 농축액(사과즙, 토마토즙, 다시마즙, 또는 인삼즙)을 이용하여 제조한 음료 100ml에 첨가한 것을 제외하고는 제조예 1과 동일하게 제조하였다.Except that 0.15 g of Hovenia dulcis extract was added to 100 ml of a beverage prepared by using juice of various fruits, vegetables, seaweeds, beans, natural medicines or the like or its extract concentrate (apple juice, tomato juice, kelp juice or ginseng juice) Was prepared in the same manner as in Preparation Example 1.
5. 제조예 55. Preparation Example 5
헛개나무 추출물 0.5g을 피로해소제 음료 100ml에 첨가한 것을 제외하고는 제조예 1과 동일하게 제조하였다.The preparation was carried out in the same manner as in Preparation Example 1, except that 0.5 g of Hovenia dulcis extract was added to 100 ml of the fatigue eliminating drink.
6. 제조예 66. Preparation Example 6
헛개나무 추출물 0.5g을 알코올성 음료 100ml에 첨가한 것을 제외하고는 제조예 1과 동일하게 제조하였다.The preparation was carried out in the same manner as in Preparation Example 1 except that 0.5 g of Hovenia dulcis extract was added to 100 ml of an alcoholic beverage.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120032467A KR101468467B1 (en) | 2012-03-29 | 2012-03-29 | A composition comprising an extract of Hovenia dulcis for decreasing stress |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120032467A KR101468467B1 (en) | 2012-03-29 | 2012-03-29 | A composition comprising an extract of Hovenia dulcis for decreasing stress |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130110465A true KR20130110465A (en) | 2013-10-10 |
KR101468467B1 KR101468467B1 (en) | 2014-12-03 |
Family
ID=49632271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120032467A KR101468467B1 (en) | 2012-03-29 | 2012-03-29 | A composition comprising an extract of Hovenia dulcis for decreasing stress |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101468467B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050105910A (en) * | 2004-05-03 | 2005-11-08 | 박근형 | Extracted Preparation of Hovenia dulcis Thunb for Antioxidative Function Containing Quercetin 3-O-α- L-rhamnoside, Kaempferol 3-O-α- L-rhamnoside, Kaempferol 3,7-O-α- L-dirhamnoside, Caffeine, Kaempferol 3-O-α- L-rhamosyl(1→6)-O-β- D-glucosyl(1→2)-O-β- D-glucoside, and Kaempferol 3-O-α- L-rhamoside-7-O-[β- D-glucosyl-(1→3)-α- L-rhamnoside] |
-
2012
- 2012-03-29 KR KR1020120032467A patent/KR101468467B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101468467B1 (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102293273A (en) | Health tea capable of adjusting blood pressure, blood sugar and blood fat and preventing thrombus and apoplexy | |
CN104054769A (en) | Functional bread for treating cardiovascular disease and making method of functional bread | |
CN105901452A (en) | Tartary buckwheat beverage and preparation method thereof | |
CN103830496A (en) | Blood glucose reduction resistant composition | |
KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
CN105412277A (en) | Traditional Chinese medicinal composition of lipid-lowering tea and application of traditional Chinese medicinal composition | |
KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
KR102170090B1 (en) | A composition comprising the complex extract for antiobesity of men | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
CN104887760A (en) | Ganoderma spore powder wine and preparation method thereof | |
KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
KR102282839B1 (en) | Composition for relieving or improving hangover | |
KR101468467B1 (en) | A composition comprising an extract of Hovenia dulcis for decreasing stress | |
CN102657351A (en) | Anti-aging medicated diet beverage, preparation method and application of anti-aging medicated diet beverage | |
KR20100089910A (en) | Composition comprising the mixed herbal extract for preventing and treating hyperlipidemia and diabetic hyperlipidemia | |
CN104474337A (en) | Preparation method of Chinese patent health granule containing green tea extract | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR102467125B1 (en) | Method for Preparing Aralia continentalis extract with enhanced Kaurenoic acid and continentalic acid contents | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
KR20100108869A (en) | Composition containing extract of herbal mixture for prevention or treatment of diabetes | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
CN104547909B (en) | A kind of Chinese medicine composition of reducing blood lipid and preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20171127 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20181126 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191111 Year of fee payment: 6 |